| Company/Division name | Amgen |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Total number of jobs (added or to be added): | 400 |
| Year reshoring announced: | 2021 |
| Year reshoring implemented or to be implemented: | 2024 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | $365 |
| City reshored to: | Columbus |
| State(s) reshored to: | OH |
| If relevant, work nearshored to: | - |
| Industry(ies): | Medical Equipment & Supplies |
| Product(s) reshored | vials, syringes |
| What non-domestic negative factors made offshoring less attractive? | Total cost |
| What domestic positive factors made reshoring more attractive? | Automation/technology, Eco-system synergies, Infrastructure, Skilled workforce availability/training |
